FDA To Review , Rules Regarding Manufacturing , Infant Formula .<br />On November 15, the United States Food and Drug Administration said it would review guidance and rules regarding the manufacturing of infant formula.<br />On November 15, the United States Food and Drug Administration said it would review guidance and rules regarding the manufacturing of infant formula.<br />Fox News reports that the decision is part of the U.S. health <br />regulator's strategy to prevent bacterial illness similar <br />to that found in Abbot Laboratories' products this year.<br />Fox News reports that the decision is part of the U.S. health <br />regulator's strategy to prevent bacterial illness similar <br />to that found in Abbot Laboratories' products this year.<br />The FDA will also reportedly weigh whether to establish a dedicated group of investigators to facilitate regulatory oversight of infant formula.<br />The regulator is considering realigning its <br />staff across two of its divisions to better <br />support oversight, among other new measures. .<br />The regulator is considering realigning its <br />staff across two of its divisions to better <br />support oversight, among other new measures. .<br />The announcement comes after a major <br />baby formula shortage earlier this year <br />that sent parents in the U.S. scrambling. .<br />The shortage was caused by a shutdown at Abbott's <br />Michigan plant after complaints of infection by <br />a bacteria known as cronobacter sakazakii.<br />The shortage was caused by a shutdown at Abbott's <br />Michigan plant after complaints of infection by <br />a bacteria known as cronobacter sakazakii.<br />Fox News reports that while the bacterial<br />infection is considered rare, <br />it can be deadly to newborns.<br />Abbott's baby formula products <br />were recalled after reports <br />of four cases and two deaths.<br />In September, the FDA said that its response <br />to the infant formula shortage was hampered <br />by delays and outdated technology.<br />In September, the FDA said that its response <br />to the infant formula shortage was hampered <br />by delays and outdated technology.<br />In a 10-page report, the FDA said that "inadequate processes and lack of clarity" related to whistleblower complaints could have slowed the agency's response.<br />In a 10-page report, the FDA said that "inadequate processes and lack of clarity" related to whistleblower complaints could have slowed the agency's response
